Ningbo Menovo Pharmaceutical's subsidiary obtains registration certificate for clopidogrel bisulfate tablets.

Ningbo Menovo Pharmaceutical (603538.SH) announced that its wholly-owned subsidiary, Ningbo Menovo Pharmaceutical Tiankang Pharmaceutical Co., Ltd. (referred to as "Ningbo Menovo Pharmaceutical Tiankang"), recently received the Drug Registration Certificate for Clopidogrel Bisulfate Tablets issued by the National Medical Products Administration. The indications for this medicine are: used for secondary prevention of atherothrombotic events in the following patients: patients with recent myocardial infarction (from several days to less than 35 days), recent ischemic stroke patients (from 7 days to less than 6 months), or patients diagnosed with peripheral arterial disease. Patients with acute coronary syndrome: i. Non-ST segment elevation acute coronary syndrome (including unstable angina or non-Q wave myocardial infarction), including patients who have undergone percutaneous coronary intervention with stent placement, in combination with aspirin. ii. Used in patients with ST-segment elevation acute coronary syndrome in combination with aspirin, and can be used concurrently with thrombolytic therapy. The issuance of the Drug Registration Certificate for Clopidogrel Bisulfate Tablets by the National Medical Products Administration signifies that the company has obtained the qualification to produce and sell this medicine in the domestic market, enhancing the company's product market competitiveness and further enriching the company's formulation product pipeline. This is expected to have a positive impact on the company's business development.